FEMY Key Statistics, Chart & Performance
The current stock price of FEMY is 0.8503 USD. In the past month the price increased by 35.44%. In the past year, price decreased by -20.54%.
FEMY Latest News, Press Relases and Analysis
FEMY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.41 | 220.47B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.01 | 201.47B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.37 | 145.93B | ||
| SYK | STRYKER CORP | 28.01 | 141.09B | ||
| IDXX | IDEXX LABORATORIES INC | 58.27 | 58.67B | ||
| BDX | BECTON DICKINSON AND CO | 13.35 | 55.18B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.99 | 49.20B | ||
| RMD | RESMED INC | 25.58 | 36.96B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.77 | 37.16B | ||
| DXCM | DEXCOM INC | 34.95 | 25.35B | ||
| PODD | INSULET CORP | 67.31 | 21.64B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.76 | 18.85B |
Related stock screener links
About FEMY
Company Profile
Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company is headquartered in Suwanee, Georgia and currently employs 69 full-time employees. The company went IPO on 2021-06-18. The firm is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The firm has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The company also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Company Info
FEMASYS INC
3950 Johns Creek Court, Suite 100
Suwanee GEORGIA US
CEO: Kathy Lee-Sepsick
Employees: 70
Phone: 17705003910
FEMASYS INC / FEMY FAQ
What does FEMASYS INC do?
Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company is headquartered in Suwanee, Georgia and currently employs 69 full-time employees. The company went IPO on 2021-06-18. The firm is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The firm has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. The company also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Can you provide the latest stock price for FEMASYS INC?
The current stock price of FEMY is 0.8503 USD. The price decreased by -4.46% in the last trading session.
What is the dividend status of FEMASYS INC?
FEMY does not pay a dividend.
What is the ChartMill technical and fundamental rating of FEMY stock?
FEMY has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for FEMASYS INC?
FEMASYS INC (FEMY) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
What is the outstanding short interest for FEMASYS INC?
The outstanding short interest for FEMASYS INC (FEMY) is 5.47% of its float.
FEMY Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to FEMY. When comparing the yearly performance of all stocks, FEMY is one of the better performing stocks in the market, outperforming 94.76% of all stocks.
FEMY Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FEMY. FEMY has a bad profitability rating. Also its financial health evaluation is rather negative.
FEMY Financial Highlights
Over the last trailing twelve months FEMY reported a non-GAAP Earnings per Share(EPS) of -0.71. The EPS increased by 12.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -152.51% | ||
| ROE | -1394.22% | ||
| Debt/Equity | 4.03 |
FEMY Forecast & Estimates
9 analysts have analysed FEMY and the average price target is 5.78 USD. This implies a price increase of 579.76% is expected in the next year compared to the current price of 0.8503.
For the next year, analysts expect an EPS growth of 29.2% and a revenue growth 8.11% for FEMY